MRC MHU
@MRC_MHU
Followers
905
Following
1K
Media
99
Statuses
1K
Latest news and research updates from the MRC Molecular Haematology Unit @MRC_WIMM @UniOfOxford
Oxford, England
Joined August 2016
At the MRC MHU we believe that studying the molecular science underpinning medicine gives us the power to transform healthcare. 🧫🔬🩺 https://t.co/rfDzSMfCas
0
1
5
🧵Just out in Blood @BloodPortfolio: Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy https://t.co/aT9L5oSpKj We study how resistance and durable remission emerge in IDH1-mutant AML.
ashpublications.org
Key Points. Ivosidenib, venetoclax ± azacitidine either rapidly selects evolved, resistant leukemic clones or eradicates leukemic clones.Resistant clones e
2
11
32
Congratulations to Adam Wilkinson, who has received the 2025 Janet Rowley Award from the @ISEHSociety for his outstanding contributions to the field of hematopoietic stem cell biology 🎉 Read more: https://t.co/6xlWVge4dy
@awilkinsongroup | @RDMOxford
imm.ox.ac.uk
Associate Professor Adam Wilkinson has received the 2025 Janet Rowley Award from the International Society for Experimental Haematology for his outstanding contributions in the field of hematopoietic...
0
5
13
For International Women's Day tomorrow, we asked some of our women scientists, including @MiraKassouf & @DrSarahGooding, to reflect on why this day is so important. #IWD2025 #InternationalWomensDay Watch:
0
9
15
The sequencing of treatments in #MultipleMyeloma is a highly complex topic. What factors should clinicians consider when making sequencing decisions & how may approaches be personalized in the future? Hear from @DrSarahGooding of @MRC_MHU: 👉 https://t.co/lFxsrfjj6O 👈 #MMSM
vjhemonc.com
Sarah Gooding, MD, PhD, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, outlines key factors to consider when making sequencing decisions in patients with multiple...
0
1
4
To conclude our @rarediseaseday series, we spoke with @el_louka26, a clinician scientist researching Paediatric Myelodysplastic Syndromes & Juvenile Myelomonocytic Leukaemia - very rare childhood cancers with no current treatment options available. Watch:
0
3
6
For Rare Disease Day this Friday, we spoke with @DrSarahGooding, a clinician scientist in @Chapman_lab_UK at the MRC WIMM researching multiple myeloma, a currently incurable type of bone marrow cancer that desperately requires friendlier therapies. Watch:
0
5
7
🎥 Abdullah Khan (@AbAttacks) of @MRC_WIMM discusses the engineering of physiologically complex human pre-clinical models and their applications for #MultipleMyeloma: 👉 https://t.co/bUIcHA0xt0 👈 #MMSM #Myeloma #HemOnc
vjhemonc.com
In this video, Abdullah Khan, BSc (Hons), MRes, PhD, MRC Weatherall Institute of Molecular Medicine, Oxford, UK, discusses the engineering of complex human pre-clinical models and their applications...
0
1
3
NEW preprint from @AbAttacks & colleagues:
Good morning everyone, I'm pleased to share our latest advance in bone marrow in vitro modelling: https://t.co/2Sa2lAGkeD
0
1
1
At the MRC WIMM, we foster a strong culture of innovation. We spoke with some of our current and former Group Leaders who have developed their discoveries into commercial ventures to translate their research into clinics and benefit patients:
0
5
5
Well done @ling_r for presenting your DPhil project at OCH Day @MRC_WIMM @OxfordCancer @OxPaediatrics
0
2
16
Happy to share this story where we show selection of therapy-resistant clones in patients treated for IDH1-mutant myeloid malignancy months to years before relapse. This has been a great collaboration between researchers from @MRC_WIMM and @MDAndersonNews. 🧵 below.
🔥Pre-print🔥 We show that therapy-resistant clones are selected within 1-3 cycles of IVO+VEN+/-AZA, months or years before relapse, within rare populations of persistent LSCs. Consistently, in patients with sustained remission, only WT/CH cells persist. https://t.co/2Q7rD7ZaeL
0
1
7
On Radio 4 TODAY - Listen to @AbAttacks from the @MRC_MHU talking about how organoid research could help develop better treatments on the latest episode of Best Medicine 🧫 6:30 pm on Radio 4 or online now! https://t.co/hMhZeRdMgl
bbc.co.uk
Pain management takes on tiny beating hearts in a dish and prosthetic legs.
0
4
9
❄️ Season's Greetings from the MRC WIMM ❄️ Each year, we hold a decorating contest to fill labs and offices in the Institute with festive cheer ☃️ This year's winner was the HSCB Lab & 2nd place went to the Higgs Lab 🥳 https://t.co/2nn3s9yQsp
0
2
8
Really enjoyed doing this short interview about our research and @NaturePortfolio publication on developing models of infant leukaemia. @OxPaediatrics @MRC_MHU @MRC_WIMM @milnetom68 @SiobhanRice12 @wellcometrust @bloodcancer_uk
Learn how Nature Portfolio authors like @andiroy are changing the world through groundbreaking research, from influencing climate policy to restoring mobility after spinal injuries. Read more in the latest blog. https://t.co/oPgNtusjOn
2
3
32
Congratulations Alastair for a great talk at ASH @MRC_WIMM @andiroy #chromatin #enhancers #genome_architecture:
1
3
32
With just under 2 weeks left to apply for our DPhil programme, watch some of our students and group leaders break down why the MRC WIMM's collaborative environment is the ideal place for research 🧬 🔬 https://t.co/fVLUJ90oF3 Apply here: https://t.co/pDbKLhW8Ku Deadline for RDM
0
6
7
Last week, we were delighted to host a visit from @bloodcancer_uk staff and community supporters. It was a fantastic opportunity to connect with some of the people who make our research possible and to show first-hand how their support is driving meaningful progress.
0
3
15
Interested in involving the public in your research? Join our webinar on 26 November and hear from public partners about their involvement in lab-based research and strategy. Register: https://t.co/x2VF2IRHeX
0
15
19